NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Approximately 5 percent of patients with metastatic colorectal cancer have MSI-H or dMMR tumors. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

People want to extend their lives for years, not just shrink their tumors for months, and if you are happy with 40% tumor response rates on 5% of solid tumors, then your work is done here. No need to see what comes next.